Amylyx
Healthcare & Life Sci
Company overview
Amylyx is a biopharmaceutical company that develops experimental therapies aimed mainly at treating neurodegenerative diseases. Its main product, AMX0035, is a combination of taurursodiol and sodium phenylbutyrate designed to protect nerve cells. The company was established in 2013 by Joshua Cohen and Justin Klee.
Amylyx is headquartered in Cambridge, Massachusetts.
- Industry
- Healthcare & Life Sci
- Headquarters
- Cambridge, United States